Trial · NCT03181893
Results by group389
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 389
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Stage 1) Placebo | -3.44 | Standard Deviation 5.270 | Units on a scale | |
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | PF-06823859 600 mg IV (Stage 1) | -19.62 | Standard Deviation 9.140 | Units on a scale | |
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Stage 2) Placebo | 5.00 | Units on a scale | ||
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Stage 2) PF-06823859 150 mg IV | -17.40 | Standard Deviation 9.290 | Units on a scale | |
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Stage 2) PF-06823859 600 mg IV | -26.00 | Standard Deviation 7.937 | Units on a scale | |
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Amended Stage 2) Placebo Then Switched to PF-06823859 150 mg IV at Week 12 | -3.00 | Standard Deviation 8.485 | Units on a scale | |
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Amended Stage 2) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | 3.00 | Units on a scale | ||
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Amended Stage 2) PF-06823859 150 mg IV Then Switched to Placebo at Week 12 | -16.40 | Standard Deviation 5.835 | Units on a scale | |
| Change From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) Activity Score at Week 12 (Stage 1, Stage 2 and Amended Stage 2) | (Amended Stage 2) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | -15.33 | Standard Deviation 6.028 | Units on a scale | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3) | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | TEAEs | 7 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3) | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | TEAEs | 8 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3) | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | SAEs | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) (Stage 3) | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | SAEs | 2 | Participants | |
| Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3) | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | 0 | Participants | ||
| Number of Participants With Clinically Significant Laboratory Abnormalities (Stage 3) | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | 1 | Participants | ||
| Number of Participants With Vital Sign Abnormalities (Stage 3) | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | Sitting SBP Value <90 mmHg | 0 | Participants | |
| Number of Participants With Vital Sign Abnormalities (Stage 3) | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | Sitting SBP Value <90 mmHg | 0 | Participants | |
| Number of Participants With Vital Sign Abnormalities (Stage 3) | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | Sitting DBP Value <50 mmHg | 0 | Participants | |
| Number of Participants With Vital Sign Abnormalities (Stage 3) | (Stage 3) PF-06823859 600 mg IV Then Switched to Placebo at Week 12 | Sitting DBP Value <50 mmHg | 0 | Participants | |
| Number of Participants With Vital Sign Abnormalities (Stage 3) | (Stage 3) Placebo Then Switched to PF-06823859 600 mg IV at Week 12 | Sitting Pulse Rate Value <40 bpm | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181893/results